BJDX · XBRL financial data

Bluejay Diagnostics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BJDX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,397	1,286*	1,335	1,032	552	554*	785	890	786	586*	812	1,438
Selling, general and administrative	(20)	1*	6	—	—	—	—	—	—	—	—	—
General and administrative	964	1,100*	1,087	862	809	930*	1,104	1,095	831	876*	1,127	911
Total operating expenses	2,341	2,387*	2,428	1,895	1,362	1,485*	1,889	1,985	1,617	1,462*	1,939	2,349
Operating income (loss)	(2,341)	(2,387)*	(2,428)	(1,895)	(1,362)	(1,485)*	(1,889)	(1,985)	(1,617)	(1,462)*	(1,939)	(2,349)
Interest income	—	year only	30	15	62	39*	18	29	19	32*	19	25
Interest expense	—	—	—	626	186	1*	—	0	0	0*	—	—
Other income (expense)	43	(81)*	100	(580)	9	15*	7	(0)	1	1*	1	0
Net income (loss)	(2,298)	(2,303)*	(2,328)	(2,475)	(1,482)	(1,432)*	(1,864)	(1,957)	(1,598)	(1,430)*	(1,919)	(2,324)
Earnings per share, basic USD per share	(2.08)	—	(0.99)	(5.12)	(0.16)	—	(3.37)	(1.41)	(1.01)	—	(1.95)	(1.12)
Earnings per share, diluted USD per share	(2.08)	—	(0.99)	(5.12)	(0.16)	—	(3.37)	(1.41)	(1.01)	—	(1.95)	(1.12)
Weighted average shares, basic thousands of shares	1,103	—	2,359	483	9,556	—	554	1,387	1,575	—	985	2,079
Weighted average shares, diluted thousands of shares	1,103	—	2,359	483	9,556	—	554	1,387	1,575	—	985	2,079

† Share count changed about 1/49 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (BJDX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	5,077	2,209	2,661	8,058	5,756	4,302	3,116	4,443	3,082	5,165	3,684	9,599
Prepaid and other current assets	1,451	747	789	960	812	597	456	305	169	276	270	203
Total current assets	6,528	3,221	3,450	9,018	6,568	4,899	3,572	4,749	3,353	5,464	3,967	9,815
Property and equipment, net	1,322	1,286	1,301	1,553	1,535	1,513	1,495	1,477	1,394	1,534	1,529	1,643
Right-of-use asset	367	333	299	263	227	210	176	156	135	113	91	69
Total assets	8,247	4,869	5,075	10,859	8,353	6,657	5,278	6,403	4,890	7,119	5,599	11,534
Accounts payable	756	491	272	490	317	145	520	109	161	214	220	674
Accrued liabilities	—	1,117	1,108	—	—	552	—	—	—	805	—	—
Total current liabilities	2,800	1,771	1,526	2,057	1,049	810	1,317	1,041	1,149	1,119	1,414	2,117
Lease liability, non-current	220	190	171	151	130	109	87	65	43	20	—	—
Total liabilities	3,033	1,974	1,708	2,218	1,189	928	1,412	1,113	1,197	1,144	1,417	2,119
Accumulated deficit	(24,648)	(26,951)	(29,279)	(31,755)	(33,237)	(34,669)	(36,533)	(38,490)	(40,087)	(41,517)	(43,437)	(45,761)
Total stockholders' equity	5,213	2,895	3,367	8,641	7,164	5,729	3,866	5,290	3,693	5,975	4,181	9,415
Total liabilities and equity	8,247	4,869	5,075	10,859	8,353	6,657	5,278	6,403	4,890	7,119	5,599	11,534
Common shares outstanding (cover page) thousands of shares	1,239	2,688	2,904	6,252	26,884	554	1,494	1,494	1,814	972	1,035	4,468

† Share count changed about 1/49 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal quarters (BJDX's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24†Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,298)	(2,303)*	(2,328)	(2,475)	(1,482)	(1,432)*	(1,864)	(1,957)	(1,598)	(1,430)*	(1,919)	(2,324)
Stock-based compensation	(42)*	(16)*	12	6*	5*	(3)*	1	(2)*	0*	0*	—	—
Net cash from operating activities	(1,125)*	(2,777)*	(2,296)	(1,854)*	(1,931)*	(1,739)*	(1,185)	(2,054)*	(1,360)*	(1,455)*	(1,589)	(1,499)*
Purchases of property and equipment	74*	88*	35	270*	0*	1*	—	—	—	year only	19	143*
Net cash from investing activities	(74)*	(88)*	(35)	(270)*	(0)*	(1)*	—	—	—	year only	(15)	(143)*
Proceeds from issuing common stock	—	0*	3,500	8,569*	0*	0*	—	—	0*	4,500*	125	8,500*
Net cash from financing activities	1,176*	(3)*	2,784	7,521*	(371)*	286*	(1)	3,381*	(1)*	3,711*	124	7,557*

† Share count changed about 1/49 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Bluejay Diagnostics	9,599	not reported	(1,499)*	4.5M	6.4 quarters	Q2 FY26 10-QJun 30, 2026
Interpace Biosciences	2,688	9,131	98*	27.7M	—	Q2 FY26 10-QJun 30, 2026
Global Innovative Platforms	244	51	(134)*	49.8M	1.8 quarters	Q3 FY26 10-QJun 30, 2026
ENDRA Life Sciences	1,740	not reported	(928)*	1.5M	1.9 quarters	Q2 FY26 10-QJun 30, 2026
Stimcell Energetics	6.9	not reported	(109)	21.1M	0.1 quarters	Q1 FY27 10-QAug 31, 2026
LogicMark	3,496	3,349	83*	899,759	—	Q2 FY26 10-QJun 30, 2026
INVO Fertility	3,733	2,175	(1,101)*	2.5M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Nu-Med Plus	5.4	0	1.1*	83.5M	—	Q2 FY26 10-QJun 30, 2026
STRATA Skin Sciences	7,912	9,292*	(239)*	5.9M	33.1 quarters	Q4 FY25 10-KDec 31, 2025

Not investment advice. Not affiliated with the U.S. SEC.